norethindrone acetate has been researched along with Osteoporosis in 11 studies
norethisterone acetate : A 3-oxo Delta(4)-steroid that is norethisterone in which the hydroxy group has been converted to its acetate ester.
Osteoporosis: Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation." | 6.48 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. ( Chwalisz, K; Stanczyk, FZ; Surrey, E, 2012) |
| "Postmenopausal osteoporosis affects 25 to 50% of older women and increases the risk for vertebral, hip, and other fractures." | 3.76 | The menopause. ( Gambrell, RD, 1986) |
| "25 micrograms, oestrogens/gestagen alone or combined with 1,25(OH)2D3, and placebo." | 2.65 | Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis. ( Christensen, MS; Christiansen, C; Hagen, C; Rødbro, P; Transbøl, I, 1981) |
| "Norethindrone acetate (NETA) is a unique progestin that has both estrogenic and androgenic properties and is effective as an add-back regimen without estrogen supplementation." | 2.48 | The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis. ( Chwalisz, K; Stanczyk, FZ; Surrey, E, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (63.64) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 1 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chwalisz, K | 1 |
| Surrey, E | 1 |
| Stanczyk, FZ | 1 |
| Christiansen, C | 6 |
| Rødbro, P | 2 |
| Christensen, MS | 1 |
| Hagen, C | 1 |
| Transbøl, I | 2 |
| Jensen, GF | 1 |
| Riggs, BL | 1 |
| Bjarnason, NH | 1 |
| Alexandersen, P | 1 |
| Stevenson, JC | 1 |
| Cust, MP | 1 |
| Gangar, KF | 1 |
| Hillard, TC | 1 |
| Lees, B | 1 |
| Whitehead, MI | 1 |
| Löttge, M | 1 |
| Spieler, W | 1 |
| Seifert, B | 1 |
| Hemp, O | 1 |
| Riis, BJ | 2 |
| Johansen, J | 1 |
| Gambrell, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Trial of 13-cis Retinoic Acid (Isotretinoin) for the Treatment of Men With Oligoasthenoteratozoospermia[NCT02061384] | Phase 2 | 20 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Millions of sperm per ejaculate in men treated with 13-cis retinoic acid (NCT02061384)
Timeframe: Up to 20-weeks
| Intervention | Millions of sperm per ejaculate (Median) |
|---|---|
| 13-cis Retinoic Acid | 2.5 |
| Calcitriol 0.25 mcg | 3.8 |
4 reviews available for norethindrone acetate and Osteoporosis
| Article | Year |
|---|---|
The hormonal profile of norethindrone acetate: rationale for add-back therapy with gonadotropin-releasing hormone agonists in women with endometriosis.
Topics: Bone Density; Endometriosis; Estrogens; Female; Gonadotropin-Releasing Hormone; Hot Flashes; Humans; | 2012 |
Formation-stimulating regimens other than sodium fluoride.
Topics: Anabolic Agents; Calcitriol; Diphosphonates; Growth Hormone; Humans; Insulin-Like Growth Factor I; N | 1993 |
The menopause.
Topics: Adult; Breast Neoplasms; Calcium; Clinical Trials as Topic; Coronary Disease; Estrogens; Female; Gal | 1986 |
Post-menopausal bone loss: effects of oestrogens and progestogens. A review.
Topics: Drug Therapy, Combination; Estradiol; Estrogens; Female; Humans; Norethindrone; Norethindrone Acetat | 1986 |
6 trials available for norethindrone acetate and Osteoporosis
| Article | Year |
|---|---|
Effect of 1,25-dihydroxy-vitamin D3 in itself or combined with hormone treatment in preventing postmenopausal osteoporosis.
Topics: Bone and Bones; Calcitriol; Calcium; Clinical Trials as Topic; Double-Blind Method; Drug Combination | 1981 |
Treatment of post menopausal osteoporosis. A controlled therapeutic trial comparing oestrogen/gestagen, 1,25-dihydroxy-vitamin D3 and calcium.
Topics: Aged; Bone and Bones; Calcitriol; Calcium; Clinical Trials as Topic; Double-Blind Method; Drug Combi | 1982 |
Number of years since menopause: spontaneous bone loss is dependent but response to hormone replacement therapy is independent.
Topics: Age Factors; Bone Density; Cross-Sectional Studies; Estradiol; Estrogen Replacement Therapy; Female; | 2002 |
Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women.
Topics: Absorptiometry, Photon; Administration, Cutaneous; Administration, Oral; Bone Density; Drug Administ | 1990 |
Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.
Topics: Alkaline Phosphatase; Biochemical Phenomena; Biochemistry; Bone and Bones; Calcium; Calcium-Binding | 1988 |
The menopause.
Topics: Adult; Breast Neoplasms; Calcium; Clinical Trials as Topic; Coronary Disease; Estrogens; Female; Gal | 1986 |
2 other studies available for norethindrone acetate and Osteoporosis
| Article | Year |
|---|---|
Does postmenopausal bone loss respond to estrogen replacement therapy independent of bone loss rate?
Topics: Aged; Bone and Bones; Drug Therapy, Combination; Estradiol; Estradiol Congeners; Estriol; Female; Fo | 1983 |
[Interdisciplinary diagnosis and therapy concepts in climacteric osteoporosis].
Topics: Adult; Bone and Bones; Calcium; Chlormadinone Acetate; Climacteric; Combined Modality Therapy; Ethin | 1989 |